NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality
NRx Pharmaceuticals today reported the minutes of a Type B meeting with the U.S. Food and Drug Administration’s Division of Psychiatry Products held on January 11, 2023.
